Mirtazapine Dosage for Sleep, Depression, and Anxiety

Mirtazapine is typically prescribed at 15 to 45 mg per day for depression, with most prescribers starting at 15 mg at bedtime and adjusting upward in 15 mg increments every one to two weeks. What makes mirtazapine dosing unusual compared to most antidepressants is a counterintuitive relationship between dose and sedation: lower doses tend to be more sedating than higher ones. That single quirk shapes nearly every dosing decision, from treating insomnia at doses as low as 3.75 mg to pushing toward 45 mg when depression is the primary target and daytime drowsiness is a problem.

The Standard Range for Depression

For major depression, the approved dose range runs from 15 mg to 45 mg daily, taken as a single dose at bedtime. Clinicians commonly begin at 15 mg and titrate upward. In a multicenter study of inpatients and outpatients with major depressive episodes, participants received 30 mg per day for two weeks and then 30 to 45 mg per day for the remaining six weeks, with significant improvement in depression scores by the end of the trial.¹ In practice, many people stabilize at 30 mg, though some need the full 45 mg before seeing adequate relief. Doses below 15 mg are not used for depression treatment. The drug reaches steady state in four to six days, thanks to a half-life that ranges from 20 to 40 hours, so dose changes usually need at least a week to show their full effect.²

Why Lower Doses Are More Sedating

This is the fact about mirtazapine dosing that surprises most people. At 15 mg or below, the drug’s strong blockade of histamine receptors dominates. Histamine blockade is what makes you drowsy, and at low doses, there is not enough noradrenergic activity to counterbalance it. As the dose climbs toward 30 or 45 mg, the noradrenergic effects ramp up and partly offset the sedation, so patients often feel less groggy at higher doses than they did at lower ones.³ This inverse dose-response relationship is genuinely unusual among psychiatric medications and has practical consequences. If a patient finds 15 mg too sedating, the counterintuitive move of increasing the dose can actually reduce the drowsiness rather than worsen it.

Low-Dose and Ultra-Low-Dose Use for Insomnia

Because mirtazapine is most sedating at low doses, clinicians have long used it off-label for chronic insomnia at doses well below the antidepressant range. A retrospective study of veterans with insomnia disorder found that ultra-low-dose mirtazapine at just 3.75 mg produced a clinically meaningful drop in insomnia severity scores within one to three months, with about half the patients showing a significant decrease and roughly a third achieving recovery-level scores.⁴ The appeal of these very low doses is less residual sedation the next day.

A randomized crossover trial in healthy volunteers exposed to noise-induced insomnia found that low-dose mirtazapine increased total sleep time by about half an hour and reduced nighttime awakenings by roughly 35 to 40 percent compared to placebo. Mirtazapine specifically boosted deep sleep (stage N3), while quetiapine, used in the same trial, increased a lighter sleep stage instead.⁵ Both drugs caused daytime sleepiness and reduced sustained attention, so the trade-off between sleep quality and next-day alertness is real even at low doses.

A retrospective comparison of mirtazapine and trazodone for chronic insomnia found that the lowest doses of each drug produced the highest percentage of responders. For mirtazapine, 7.5 mg corresponded to the best response rate, and patients on lower doses (7.5 to 15 mg) had significantly better outcomes than those pushed to 15 to 30 mg for sleep.⁶ Both drugs worked in over 85 percent of patients regardless of sex or age. This aligns with the pharmacology: for sleep, you want the histamine blockade without the activating noradrenergic push that comes at higher doses.

Weight Gain and Appetite Stimulation

Weight gain is the side effect that causes the most concern and, paradoxically, the side effect that makes mirtazapine useful in some clinical situations. Among antidepressants, mirtazapine is one of the most likely to cause weight gain, alongside older tricyclics like amitriptyline.⁷ The appetite-stimulating effect ties back to the same histamine blockade that causes sedation: histamine receptor antagonism tends to increase hunger, particularly cravings for carbohydrates. Some patients gain several kilograms within the first few months. For people already underweight or struggling with appetite loss, this can be a benefit. For others, it is the main reason they stop taking the drug.

That appetite-stimulating property has led researchers to study mirtazapine at 15 to 30 mg in patients with cancer-related cachexia and anorexia. In a phase II trial, about a quarter of patients gained at least one kilogram by week four, and appetite improved in a similar proportion.⁸ A head-to-head comparative trial in advanced oral cancer patients found that mirtazapine at 15 mg per day significantly increased appetite scores compared to olanzapine, with stronger effects on sleep, anxiety, and depression as well.⁹ A systematic review across cancer-related symptom studies concluded that mirtazapine was safe and showed effectiveness for depression, anxiety, sleep disorders, nausea, and neuropathic pain in cancer patients, though the overall quality of data was limited by small sample sizes.¹⁰

Dosing for Anxiety Disorders

Mirtazapine is not approved specifically for anxiety disorders, but there is a meaningful body of evidence supporting its use. In an open-label trial of 44 adults with generalized anxiety disorder treated with a fixed dose of 30 mg for 12 weeks, about 80 percent responded and over a third achieved remission.¹¹ A systematic review and meta-analysis found that mirtazapine performed similarly to SSRIs and benzodiazepines for generalized anxiety disorder, with no statistically significant difference in efficacy between them.¹²

For post-traumatic stress disorder, combining mirtazapine with an SSRI has shown some promise. A placebo-controlled trial found that adding mirtazapine to sertraline resulted in a significantly greater remission rate and better improvement in depressive symptoms compared to sertraline alone. The differences in overall PTSD severity did not reach statistical significance, but effect sizes favoring the combination were small to moderate across outcomes including sleep, quality of life, and functioning.¹³

Combination Therapy With Other Antidepressants

When a first-line antidepressant has not worked, clinicians sometimes add mirtazapine rather than switching entirely. The combination of mirtazapine with venlafaxine is common enough that it has picked up the informal nickname “California Rocket Fuel” among prescribers. In a study of patients with treatment-resistant depression, adding mirtazapine to venlafaxine produced a response rate of about 82 percent and a remission rate of roughly 27 percent over approximately eight weeks. Nearly half of patients had significant side effects, though only one could not tolerate the combination at all.¹⁴ A separate randomized study looked at adding mirtazapine at 30 mg per day versus switching to imipramine in patients who had not responded to 10 weeks of venlafaxine at 225 to 300 mg daily.¹⁵ The pharmacological logic is that mirtazapine’s mechanism complements that of serotonin-norepinephrine reuptake inhibitors, potentially widening the net of neurotransmitter systems being targeted.

For patients who have not responded adequately to their current antidepressant, a report on treatment-resistant cases found that about 38 percent improved on mirtazapine at a mean dose around 37 mg per day over an average follow-up of about 14 months. About one in five patients stopped the drug because of side effects including fatigue, weight gain, and nausea.¹⁶

How Genetics, Age, and Sex Influence the Right Dose

Mirtazapine is broken down primarily by two liver enzymes, CYP2D6 and CYP3A4.¹⁷ People carry different genetic variants of CYP2D6, and these variants meaningfully change how fast the drug is cleared from the body. In a study of healthy volunteers, people with extra copies of the CYP2D6 gene (ultrarapid metabolizers) cleared mirtazapine roughly two and a half times faster than those without extra copies. Their peak blood levels were correspondingly lower.¹⁸ At the other end of the spectrum, poor metabolizers, who lack functional CYP2D6, accumulate higher drug levels. A study of steady-state blood concentrations in psychiatric patients confirmed that poor metabolizers had significantly higher levels of the active form of mirtazapine compared to people with normal enzyme function, even after accounting for age, sex, and smoking.¹⁹

Sex and age matter too. In a study of Spanish volunteers, women had somewhat different drug exposure than men after the same dose, with differences reaching statistical significance.²⁰ A large therapeutic drug monitoring study of 328 psychiatric patients found that women had about 18 percent higher dose-adjusted drug levels than men, and patients over 65 had roughly 27 percent higher levels than younger patients at the same dose.²¹ That same study found that 38 percent of patients had blood levels below the therapeutic reference range and 8 percent were above it, suggesting that standard doses leave many people either under-treated or over-exposed. Smoking also lowered mirtazapine levels significantly, meaning smokers may need higher doses to reach the same blood concentrations as nonsmokers.²²

None of this means you need genetic testing before starting mirtazapine. But if you’re taking a standard dose and getting either too many side effects or too little benefit, the explanation may be pharmacogenetic rather than psychological. Some clinics now offer CYP2D6 genotyping as part of routine psychiatric care, and the results can guide dose adjustments.

Safety in Overdose

Mirtazapine stands out among antidepressants for its relatively mild overdose profile. A five-year review of 117 cases admitted to a toxicology unit found that the median dose ingested in overdose was 450 mg, roughly ten to thirty times a normal daily dose. Despite these quantities, reduced consciousness occurred in about 27 percent of patients, and tachycardia in about 30 percent. There were no deaths, no serious heart rhythm abnormalities, and no other significant laboratory or ECG abnormalities. When severe toxic features occurred, they could be attributed to other drugs or alcohol taken at the same time.²³

A separate study of 88 single-agent mirtazapine overdoses reached similar conclusions. Tachycardia occurred in a third of cases and high blood pressure in about a third, but there were no arrhythmias, no heart rhythm conduction abnormalities, no QT prolongation, no intensive care admissions, and no deaths. The typical hospital stay was about 14 hours.²⁴ This safety margin is one reason mirtazapine is sometimes preferred for patients at higher risk of self-harm, compared to tricyclic antidepressants or certain other agents where overdose can be far more dangerous.

Tapering and Discontinuation

Stopping mirtazapine abruptly after prolonged use can produce withdrawal symptoms including rebound insomnia, nausea, irritability, and dizziness. Current deprescribing guidance recommends gradual tapering rather than sudden cessation. Because mirtazapine’s effect on receptors does not decrease in a straight line as the dose drops, some experts advocate hyperbolic tapering: making progressively smaller dose reductions as you get closer to zero. For example, going from 30 mg to 15 mg is a smaller relative change in receptor occupancy than going from 15 mg to zero, so the final steps need to be the smallest.

Practically, this is complicated by the fact that mirtazapine does not come in a liquid form from the manufacturer. One workaround involves dispersing a 15 mg tablet in water to create a rough suspension, allowing patients to measure out very small doses using a syringe. Compounding pharmacies can also prepare custom liquid formulations.²⁵ If you are planning to come off mirtazapine, working out a detailed taper schedule with your prescriber is worth the effort. Rushing the process is one of the most common reasons people experience unnecessary withdrawal discomfort.

Use in Children and Adolescents

Mirtazapine is not approved for pediatric use, and the evidence base is thin compared to SSRIs. An open-label pilot study in adolescents with major depression found that mirtazapine showed marked efficacy on rating scales, was well tolerated, and had a beneficial effect on sleep. No participants dropped out due to adverse events, though tiredness, increased appetite, and dizziness were common.²⁶ Without a placebo arm, it is hard to know how much of that improvement reflects the drug itself versus natural recovery or placebo response, which tend to be high in adolescent depression trials.

A more rigorous randomized placebo-controlled pilot trial looked at mirtazapine for anxiety in children and adolescents with autism spectrum disorder. Within the mirtazapine group, anxiety scores improved significantly. However, when compared head-to-head with placebo, the difference was clinically meaningful but did not reach statistical significance, likely because the trial was small. About 47 percent of participants on mirtazapine were rated as much improved or very much improved, versus 20 percent on placebo. There were no significant differences in adverse effects between the groups.²⁷ The researchers concluded that a larger trial is warranted, which is the diplomatic way of saying the signal is promising but unproven.

Pregnancy and Breastfeeding

A systematic review covering 390 neonates exposed to mirtazapine during pregnancy or lactation found no increased risk of major birth defects. There was a possible association with spontaneous abortion, but the reviewers could not separate that from the effects of the underlying psychiatric illness itself, which independently raises miscarriage risk. One study noted a nearly significant increase in respiratory problems and low blood sugar in newborns, but no causal link could be established. Limited data on breastfeeding, covering 11 exposed infants across four publications, suggested that mirtazapine’s transfer into breast milk results in a low relative infant dose, making it likely safe during nursing.²⁸ The evidence here is reassuring but not extensive. Decisions about continuing or starting mirtazapine during pregnancy are best made individually, weighing the risk of untreated depression or anxiety against the uncertainties of fetal exposure.

Daytime Impairment at Different Doses

One concern that runs through all dosing decisions is how much the drug affects functioning the next day. A study comparing repeated dosing of mirtazapine and trazodone in healthy volunteers using a standardized driving simulation found that mirtazapine significantly worsened driving performance (as measured by lateral drift) compared to trazodone on the second day of dosing. Mirtazapine also increased subjective sleepiness scores more than trazodone or placebo.²⁹ For people taking mirtazapine primarily for sleep, this is the core trade-off: the drug reliably improves nighttime sleep quality, but at some doses it bleeds into the next morning. The inverse dose-response relationship described earlier means that going to a slightly higher dose can paradoxically reduce this next-day grogginess, but it is not guaranteed, and some people remain sedated across the entire dose range. Giving the drug early enough in the evening, rather than just before bed, is a simple adjustment that helps some people clear the worst of the sedation by morning.